KT-US-982-5968
Research type
Research Study
Full title
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
IRAS ID
330559
Contact name
David Cunningham
Contact email
Sponsor organisation
Kite Pharma, Inc
Clinicaltrials.gov Identifier
Duration of Study in the UK
15 years, 0 months, 1 days
Research summary
This is a long term follow up study for patients that have received an experimental gene-modified cell therapy treatment in a previous study sponsored by Kite Pharma, Inc. The purpose of this study is to monitor participants for any delayed side effects that may be related to the gene-modified cell therapy treatment that they have received. These participants will be monitored for up to 15 years and will require participants to visit the hospital every 3-6 months for the first 3 years followed by yearly visits until the study ends or the participant completes all of the study visits required. During these visits participants will complete questionnaires and blood tests to monitor their overall health and wellbeing.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
23/NW/0289
Date of REC Opinion
10 Oct 2023
REC opinion
Further Information Favourable Opinion